Logotype for Donaldson Company Inc

Donaldson (DCI) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Donaldson Company Inc

Q3 2026 earnings summary

2 Jun, 2026

Executive summary

  • Achieved record third quarter sales of $995.1 million, up 5.8% year-over-year, with all-time high adjusted operating margin and EPS, driven by strong Mobile Solutions and Life Sciences growth, and disciplined expense management.

  • Net earnings more than doubled to $118.1 million, with diluted EPS rising to $1.00; adjusted EPS increased 7.1% to $1.06.

  • Successfully closed the Facet Filtration acquisition for $828.7 million, expanding high-margin recurring revenue and the Industrial Solutions portfolio.

  • Completed final plant closures under footprint optimization, shifting focus to ramping up productivity at new sites for future efficiencies.

  • Returned $35 million to shareholders via dividends in Q3; year-to-date dividends paid totaled $104.0 million, with share repurchases of $108.5 million.

Financial highlights

  • Q3 sales reached $995.1 million, up 5.8% year-over-year, with a 2% benefit from pricing.

  • Adjusted EPS was $1.06, up 7% year-over-year; operating margin reached 16.6%, up 30 basis points from prior year.

  • Gross margin was 33.5%, down from 34.2% last year; adjusted gross margin was 34.4%, down 10 basis points year-over-year due to temporary inefficiencies.

  • Adjusted operating income rose 8% year-over-year; adjusted EBITDA for the quarter was $195.2 million, up from $183.0 million last year.

  • Adjusted free cash flow for the quarter was $111.6 million, with a cash conversion ratio of 89.0%.

Outlook and guidance

  • Fiscal 2026 organic sales expected to grow 3%–5%, with pricing and currency each contributing over 1%.

  • Adjusted EPS guidance set at $3.94–$4.01, up 7–9% year-over-year; Facet acquisition to dilute EPS by ~$0.03.

  • Adjusted operating margin forecast at 15.8%–16.2%; capital expenditures expected at $60–$75 million; free cash flow conversion 85%–95%.

  • Life Sciences segment sales outlook raised to 9%–11% for FY26.

  • Management expects sufficient liquidity to fund operations, debt service, dividends, share repurchases, and acquisitions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more